

SPECIALTY GUIDELINE MANAGEMENT

MAVENCLAD (cladribine)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

Mavenclad is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of Mavenclad is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternative drug indicated for the treatment of MS.

Limitations of Use

Mavenclad is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

All other indications are considered experimental/investigational and are not a covered benefit.

II. PRESCRIBER SPECIALTIES

This medication must be prescribed by or in consultation with a neurologist.

III. CRITERIA FOR INITIAL APPROVAL

Multiple Sclerosis

A. Initial requests

Authorization of 45 days may be granted for treatment of relapsing forms of multiple sclerosis (including relapsing-remitting and secondary progressive disease for those who continue to experience relapses) and when all of the following criteria are met:

1. Inadequate response or unable to tolerate two disease-modifying drugs indicated for the treatment of multiple sclerosis.
2. Member does not have clinically isolated syndrome (CIS).
3. Member has not received 2 courses (i.e., 4 cycles) of Mavenclad.
4. Members will not use Mavenclad concomitantly with other medications used for the treatment of multiple sclerosis, excluding Ampyra.

B. Subsequent requests

Authorization of 45 days may be granted for treatment of relapsing forms of multiple sclerosis (including relapsing-remitting and secondary progressive disease for those who continue to experience relapses) and when all of the following criteria are met:

1. Member has not received 2 courses (i.e., 4 cycles) of Mavenclad.
2. Members will not use Mavenclad concomitantly with other medications used for the treatment of multiple sclerosis, excluding Ampyra.
3. The member has not received Mavenclad in the last 43 weeks.

IV. QUANTITY LIMIT

Mavenclad 10mg tablets: 20 tablets per 270 days

Effective Date: 12/2019
Reviewed: 9/2019, 6/2020, 3/2021, 3/2022
Scope: Medicaid

V. REFERENCES

1. Mavenclad [package insert]. Rockland, MA: EMD Serono; February 2022.
2. Giovannoni, G., Comi, G., Cook, S., et al. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. N Engl J Med 2010;362:416-426.